Photo credit: www.sciencedaily.com
New Insights into Psoriasis Uncovered: The Role of Hepcidin
Recent scientific investigations have pointed towards hepcidin, a hormone traditionally recognized for its role in iron regulation, as a potential trigger for psoriasis. This chronic skin condition affects approximately 2-3% of the global population, leading to severe discomfort and impacting patients’ quality of life.
In a groundbreaking study, researchers, including Dr. Charareh Pourzand from the University of Bath in the UK, propose that hepcidin may be crucial in understanding the onset of psoriasis. This marks a significant shift in how the condition is approached, with hepcidin now being viewed as a possible causal agent rather than merely a biological byproduct.
The implications of this research could be profound, especially for individuals suffering from pustular psoriasis (PP), a severe and resistant form of the illness that often has led to damage not just to the skin but also to nails and joints. The research team aspires to develop targeted treatments that could inhibit hepcidin’s action, offering new hope for these patients.
Dr. Pourzand emphasized the gravity of psoriasis, stating that it represents a lifelong challenge that can severely affect an individual’s physical and emotional health. She suggested that treatments aimed at balancing iron levels in the skin might provide much-needed relief, potentially enhancing the overall well-being of millions afflicted by this condition.
The Balance of Skin Iron: A Double-Edged Sword
Iron plays a vital role in human health, contributing to various biological functions, including collagen production and immune response, as well as facilitating oxygen transportation. However, excessive iron accumulation in the skin can lead to adverse effects, heightening the risk of chronic conditions like psoriasis by amplifying the harmful impacts of ultraviolet (UV) radiation.
For over five decades, studies have identified elevated iron levels in the skin of psoriasis patients, but the precise cause and significance of this phenomenon have remained elusive—until now. The recent study, published in the journal Nature Communications, identifies hepcidin as a crucial element linking iron accumulation to the pathology of psoriasis.
Traditionally, hepcidin is produced solely in the liver, governing dietary iron absorption. However, this new research indicates that in individuals afflicted with psoriasis, the skin also generates this hormone, contributing to abnormal iron levels.
The Hepcidin Connection: Inducing Iron Overload
In experimental studies, mice exposed to elevated levels of skin-produced hepcidin developed a version of psoriasis characterized by excessive skin cell proliferation and an influx of inflammatory neutrophils in the epidermal layer. These findings mirror key features observed in human psoriasis cases, reinforcing the notion that hepcidin may be a critical player in the disease’s pathology.
Experts acknowledge the hereditary nature of psoriasis, although they also identify environmental risk factors, such as obesity, infections, and smoking, that may contribute to its development.
The Quest for Psoriasis Treatments
Currently, psoriasis has no definitive cure. Treatment options typically include topical applications, light therapy, and systemic medications designed to manage symptoms. Recent approaches have focused on modulating immune responses to alleviate psoriasis symptoms. However, Dr. Pourzand asserts that medications targeting hepcidin could revolutionize treatment modalities across the spectrum of psoriasis manifestations.
She elaborated, stating that a hepcidin-directed drug could manage flare-ups effectively and sustain remissions, reducing the risk of recurrence. Furthermore, the use of iron chelators to regulate excess iron in psoriatic skin may help address the uncontrolled cell growth commonly seen in this condition.
Dr. William Tillett, a senior lecturer and consultant rheumatologist at the University of Bath, noted the initiative’s potential to progress understanding and treatment of psoriasis. He highlighted the opportunity new treatments could present, not just for symptom management, but potentially for preventative strategies as well. He acknowledged the limitations of existing biologic therapies, which, while effective, are expensive and not universally successful.
Dr. Penelope Pratsou, a consultant dermatologist associated with the British Skin Foundation, praised the research, emphasizing its potential to deepen the current understanding of psoriasis. However, she also advocated for further investigation into hepcidin’s role and the exploration of its applications as a potential therapeutic target.
This study is a result of collaborative efforts within Skin@Bath, a scientific network established in partnership with RUH (Bath) and the Bath Institute for Rheumatic Disease since 2017.
Source
www.sciencedaily.com